openPR Logo
Press release

With Xiaflex the only FDA approved product for this disease, Endo dominates the Peyronie’s Disease Treatment Market

01-29-2019 04:15 PM CET | Health & Medicine

Press release from: Coherent Market Insights

Peyronie’s Disease Treatment Market

Peyronie’s Disease Treatment Market

The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product is estimated to generate USD 100 million in revenue for Peyronie’s disease by 2018. In Japan, BioSpecifics Technologies Corp. has granted Asahi Kasei Pharma the rights to develop and market XIAFLEX in Japan for Peyronie's disease. Further, the company is also partnering with global companies in Canada, Europe, Mexico, and Brazil for commercializing XIAFLEX for PD.

Get Exclusive Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/61

With increasing awareness and research on this disease, new drug molecules could be made available in the market.

The exact cause of plaque formation is not known. Hence, treatment is done with the available research and knowledge of plaque formation. There are various treatment options followed for Peyronie’ disease basis on which the market is analyzed. These include drugs, surgery and devices. The drugs market can be analyzed based on the administration route i.e. oral and injectable. Drugs prescribe through oral route include Vitamin E, Potassium amino-benzoate ("Potaba"), Tamoxifen, Colchicine, and Carnitine. Similarly, the injectable drugs include Verapamil, Interferon, and Collagenase. Use of oral drugs is limited as none of the studies conducted so far for Peyroniee’s disease have shown positive results of these drugs over the placebo.

On the other hand injectables show some positive outcomes over placebo. However, more studies are required to establish the efficacy. Studies with collagenase have shown positive outcomes for its use in Peyronie's disease. Therefore, Xiaflex (Collagenase clostridium histolyticum) from BioSpecifics Technologies Corporation is the only FDA approved product indicated for Peyronie's disease in adult men. Approved in 2013, Xiaflex is marketed in the U.S. by Endo International plc. In Europe, Collagenase clostridium histolyticum is available by the brand name Xiapex.

A penile prosthetic device is another good treatment option for Peyronie's disease and moderate-to-severe ED. This device helps straighten the penis. Surgical procedure on the other hand involves grafting the space being emptied on removal of the plaque.

Peyronie's disease (PD) is condition wherein the penis is curved or bent due to development of plaque or a fibrous scar tissue inside the penis. This condition can cause painful erections and the penis gets bent while it is erected. The bent is towards the side where plaque is being formed i.e. either downwards or upwards. The condition is identified by a major bend or pain. In a few people Peyronie's disease may go away on its own. However, in most cases it may remain stable or worsen. Hence, it is advisable to visit an urologist to avoid consequences in future. Treatment may be needed if the curvature prevents successful sexual intercourse.

Read Full Report with TOC @ https://www.coherentmarketinsights.com/ongoing-insight/toc/61

Peyronie’s disease is a rare condition observed in about 6 out of 100 men in the age group of 40 to 70 years. Moreover, the Urology Care Foundation also estimates that the number of people affected by this condition can be higher than this as many men are embarrassed and do not see their healthcare provider. It is mostly at times when the men visit the healthcare practitioner for erectile dysfunction treatment and the healthcare practitioner may notice Peyronie’s disease. Lack of awareness among patients has resulted in under reporting of this condition.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release With Xiaflex the only FDA approved product for this disease, Endo dominates the Peyronie’s Disease Treatment Market here

News-ID: 1542991 • Views: 526

More Releases from Coherent Market Insights

The Global Cold Cough And Sore Throat Remedies Market Is Witnessing High Demand …
One of the most common complications from cold cough and sore throat is the inability to breathe properly. For the most part, this is usually brought on by congestive heart failure. Another common complication from influenza is the development of pneumonia, which increases the risks of infection and increases the risk of death. Some other complications from influenza include the development of Guillain Barre Syndrome and the paralytic podium symptoms. It
Flavoxate Hydrochloride Tablets Market to Witness Significant Growth, Owing to H …
Flavoxate HCL is a synthetic urinary tract spasmolytic used to treat bladder symptoms such as frequent or urgent urination, increased nighttime urination, bladder pain, and incontinence (urine leakage). According to International Continence Society, in 2018, 63 million people suffered from urgency urinary incontinence worldwide. Such high prevalence of incontinence is expected to aid in growth of the flavoxate hydrochloride tablets market. High prevalence of urinary tract infections (UTIs) is also expected
The Synthetic Hormones Market Is Rapidly Expanding Due To The High Prevalence Of …
Synthetic Hormones have enabled people with all kinds of ailments to live normal lives again. For centuries, synthetic Hormones have been used in a variety of applications by both men and women for various purposes. The earliest usage of Hormone was to prevent and treat ailments associated with reproduction, such as infertility problems and birth defects. Since then synthetic Hormones have been extensively used to treat many non-related ailments. When
North America & Europe Artificial Pancreas Systems Market Continues To Expand Ra …
Artificial Pancreas Systems have come a long way since their inception and many advancements have been made. In the past artificial pancreas was used primarily to treat diabetes. However, today there are many other conditions that mimic or even correct diabetes and this includes chronic renal failure disease (CRF). CRF is caused by a shortage in the body's natural ability to produce insulin or sugar. The primary factor aiding the

All 5 Releases


More Releases for Peyronie

Peyronie’s Disease Treatment Market Set to Encounter Paramount Growth
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
Peyronie’s Disease Market Growing Popularity and Emerging Trend by 2026
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
Peyronie’s Disease Treatment Market Is Likely to Witness Tremendous Growth by …
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
Peyronie’s Disease Market - Only FDA approved product
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
Peyronie’s Disease Treatment Market to Rear Excessive Growth With Key Players …
A penile prosthetic device is another good treatment option for Peyronie's disease and moderate-to-severe ED. This device helps straighten the penis. Surgical procedure on the other hand involves grafting the space being emptied on removal of the plaque. "With Xiaflex the only FDA approved product for this disease, Endo dominates the market" The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product.
Peyronie’s Disease Treatment Market With Major Key Players Like BioSpecifics T …
The exact cause of plaque formation is not known. Hence, treatment is done with the available research and knowledge of plaque formation. There are various treatment options followed for Peyronie’ disease basis on which the market is analyzed. These include drugs, surgery and devices. The drugs market can be analyzed based on the administration route i.e. oral and injectable. Drugs prescribe through oral route include Vitamin E, Potassium amino-benzoate ("Potaba"),